PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
Cited by 411
Related Papers
<scp>PI</scp>3K/Akt/<scp>mTOR</scp> pathway dual inhibitor <scp>BEZ</scp>235 suppresses the stemness of colon cancer stem cells
|Clinical and Experimental Pharmacology and Physiology|2015|98
Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells
|BMC Cancer|2019|54
Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis
|International Journal of Nanomedicine|2016|52
Both treated and untreated tumors are eliminated by short hairpin RNA-based induction of target-specific immune responses
|Proceedings of the National Academy of Sciences|2009|31